Challenges in Treating TP53-Mutated AML, Hope on the Horizon
https://vimeo.com/794307233 TP53-mutated acute myeloid leukemia (AML) treatment has some challenges. Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective. Learn about promising treatments on…
A Look at Ongoing Acute Myeloid Leukemia Phase III Trials
What are the acute myeloid leukemia (AML) Phase III clinical trials that are ongoing? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective about…
What Does Triplet Therapy in AML Mean for the Future?
https://vimeo.com/794307058 What do acute myeloid leukemia (AML) patients need to know about triplet therapy? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective. Learn…
A Look at Lower Intensity Chemotherapy in Untreated AML
Dr. Naval Daver from the University of Texas MD Anderson Cancer Center discusses whether untreated acute myeloid leukemia (AML) can be treated with lower intensity chemotherapy. [ACT]IVATION TIP “Ask your physician…
AML Clinical Trials Critical to Treatment Breakthroughs and Improvements
https://vimeo.com/794306889 Why are acute myeloid leukemia (AML) clinical trials so critical? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares his perspective about clinical trials. Learn…
A Look at Treatment Strategies for High-Risk AML Patients
What acute myeloid leukemia (AML) treatments are available for high-risk patients? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center discusses various mutations, potential for cure, and…
Why Is the Menin Pathway Important in AML?
https://vimeo.com/794306732 What should acute myeloid leukemia (AML) patients know about the menin pathway? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares information from ASH 2022….
The Importance of the FLT3 Mutation in AML
https://vimeo.com/794306585 What do acute myeloid leukemia (AML) patients need to know about FLT3 mutation? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center discusses considerations about the…
What Different AML Subtypes Are More Prevalent in Certain Demographics?
https://vimeo.com/794307429 Are some acute myeloid leukemia (AML) subtypes more common in some demographic groups? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center discusses different forms of…
AML Treatment Approaches Expand for Older and High-Risk Patients
https://vimeo.com/794306507 How have acute myeloid leukemia (AML) treatment approaches expanded for older and high-risk patients? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center shares insight about…
What Promising AML Treatments Are Available for Newly Diagnosed Patients?
https://vimeo.com/794306419 What do newly diagnosed acute myeloid leukemia (AML) patients have for promising treatment options? Dr. Naval Daver from the University of Texas MD Anderson Cancer Center discusses progress in…
How Can We Address Disparities in AML Among Diverse Populations?
https://vimeo.com/792475469 What do acute myeloid leukemia (AML) patients need to know about care disparities? Dr. Catherine Lai from Penn Medicine discusses ethnic disparities and other factors. Learn about factors in…